BAA-MD anderson-statistical designs and considerations for dose optimization FY25C1FP6
Active Definitive Contract Awarded Last action
- Contract number
- 75F40125C00075
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,184,156
Award facts
- Contract value 100% obligated
- $1,184,156.00 Current and potential, with all options
- Completion date 36% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Calverton, MD 20705, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $119,918 | |
| Original award | $1,064,238 |
About this award
The Food and Drug Administration awarded a $1.18M firm fixed-price definitive contract to The University of Texas MD Anderson Cancer Center for statistical designs and considerations for dose optimization. The contract, awarded September 16, 2025, with an ultimate completion date of September 29, 2028, will be performed in Calverton, Maryland. This award carries no set-aside designation, reflecting MD Anderson's competitive capabilities as a premier academic cancer research institution. The work supports FDA's regulatory and scientific objectives by leveraging MD Anderson's extensive expertise in statistical methodology and dose optimization strategies, which are critical for drug development and clinical trial design.
MD Anderson's extensive track record executing complex federal research contracts with the FDA, National Cancer Institute, and other health agencies positions the institution well for this assignment. The contract represents a component of MD Anderson's broader federal portfolio, which includes significant indefinite delivery contracts such as the $150M National Cancer Institute PREVENT Cancer Preclinical Drug Development Program. The statistical design work under this contract aligns with MD Anderson's demonstrated capabilities in biomarker evaluation, preclinical research, and translational medical services that directly support federal agencies' drug development and regulatory decision-making processes.
Quick answers
Who was awarded contract 75F40125C00075?
75F40125C00075 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Food and Drug Administration (Department of Health and Human Services) on September 16, 2025.
How much is contract 75F40125C00075 worth?
The government has obligated $1,184,156 on 75F40125C00075.
Was contract 75F40125C00075 competed?
The extent of competition for 75F40125C00075 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award